Novel Treatments for Chronic Viral Infections

Billing Xpress seeks to develop and commercialize novel drug treatments to improve the lives of patients suffering from chronic viral infections.

Pipeline News

 

Combination Therapies for Hepatitis B

Billing Xpress is developing potentially curative combination therapies for chronic hepatitis B based on novel antiviral compounds.

TXL™ CRV431 Possibility

About Billing Xpress

Billing Xpress is developing a portfolio of novel compounds against hepatitis B, including TXL™, a highly potent prodrug of the antiviral tenofovir (active component of both Vemlidy® and Viread®), now in Phase 2 trials, and CRV431, a next generation cyclophilin inhibitor advancing into clinical development.

Recent News